|
WSWS : News
& Analysis : Science
& Technology
US National Institute of Health announces new guidelines for
embryo stem cell research
By Frank Gaglioti
4 September 2000
Use
this version to print
On August 23, the National Institute of Health (NIH) published
guidelines for the public funding of embryo stem cell research
in the United States, an about-face of its previous position.
Previously embryo stem cell research was funded exclusively by
private sources. The NIH announcement lifts a ban which had been
in place on such research since 1996. President Bill Clinton welcomed
the announcement as offering potentially staggering benefits.
The new guidelines have a contradictory nature as they represent
a desire by the US government not to lose out in the race by the
US biotech industry to effectively exploit the emerging scientific
breakthroughs and at the same time an attempt to appease religious
and anti-abortion groups which have vociferously denounced embryo
stem cell research as abortions.
The new guidelines have been largely welcomed by the scientific
community and patient rights groups, but some scientists have
expressed concern at the blatant concessions to the religious
lobby. Gregory stock, the director of the program on Medicine,
Technology, and Society at the University of California at Los
Angeles, said, this is a political document. It's a very
troubling trend when you allow special-interest groups to make
minute decisions about lab procedures that have little to do with
the larger ethical and moral issues involved.
The new guidelines limit the researchers to use only cells
obtained from frozen embryos that would be discarded anyway, such
as remaining embryos from in-vitro fertilisation. The actual harvesting
of stem cells can only be carried out by privately funded scientists
and publicly funded scientists are still prohibited from obtaining
stem cells directly from embryos. Any research has to be first
approved by the Human Pluripotent Stem Cell Review Group (HPSCRG).
It is expected that any approved research is not likely to get
under way until the end of 2001.
The Clinton administration is walking a tightrope. The whole
history of the funding of stem cell research represents the White
House's attempt to serve the needs of investment brokers and at
the same time try to avoid alienating the Christian Right and
the Catholic Church. In 1994, the Human Embryo Research Panel,
a body convened by the NIH, concluded that embryonic stem cell
research should be publicly funded, as long as embryos were not
originally created for research purposes. Clinton rejected the
recommendation and banned the use of taxpayer funding for research
with human embryos, regardless of the source of the embryos. The
ban was strengthened in 1995 and 1998.
In January 1999, the Department of Health and Human Services
(HHS) announced that the federal government could fund research
on embryonic stem cells harvested from embryos which are destroyed
through research. The HHS used a legal loophole arguing that
human embryonic stem cells are not a human embryo within the statutory
definition because the cells do not have the capacity
to develop into a human being even if transferred to the uterus,
thus their destruction in the course of research would not constitute
the destruction of an embryo. In other words, the destruction
of such cells could not be considered an abortion as they would
not further develop if placed into a womb. This legal manoeuvre
only served to enrage the various religious groups, which flooded
the NIH public inquiry early this year with objections to the
new proposals.
The timing of the publication of the guidelines is very revealing
as it was previously thought that any announcement would be delayed
until after the presidential elections so as not to embarrass
Democratic candidate Vice President Al Gore by raising such a
contentious issue. The NIH had produced draft guidelines in December
1999, but suddenly moved to announce the new arrangements, coinciding
with recent moves to approve embryonic stem cell research in the
United Kingdom and Europe.
The UK proposal is far less restrictive and more far-reaching
in its scope than the US guidelines. Recommendations for embryonic
stem cell research were put forward by the Chief Medical Officer
in England, Professor Liam Donaldson on August 16. British scientists
will be given the right to clone human cells. This involves taking
a human egg and inserting a nucleus from another cell. The resulting
cell then acts as a normally fertilised egg and develops into
an embryo. Scientists can obtain stem cells from the cloned embryos.
The Blair government has announced its acceptance of the guidelines
and legislation facilitating them will be presented to the British
parliament before the end of the year. Holland and France are
expected to announce their guidelines permitting the use of embryonic
stem cells in the next few months.
Even though the first embryonic stem cells were discovered
in 1998, a number of biotechnology companies have already emerged
to exploit the potentially lucrative discoveries. The NIH announcement
was greeted positively by Wall Street, with a number of biotech
companies based on stem cell research making considerable gains.
The stocks of Aastrom Biosciences Inc. of Ann Arbor, Michigan
rose by 71 percent and StemCells Inc. of Sunnyvale, California
by 37 percent.
The new guidelines will enable a flow of discoveries from publicly
funded research facilities, which private industry will be able
to exploit for its own profit. Such a strategy was used in the
mapping the human genome. The publicly funded Human Genome Project
(HGP) produced data which was made available on the Internet within
24 hours, enabling private companies such as Celera Genomics to
use the public data to confirm their own work and so map the whole
genome in a much shorter time than if they had to rely on their
own research.
The flow of discoveries has fueled a massive influx of investment
funds into biotechnology companies. In the first half of this
year $22.1 billion went into the biotechnology industry, well
above the $12 billion invested in 1999. In March, Celera Genomics
issued stock worth $1 billion in a secondary stock offering and
in June, Celera announced its purchase of Geron Corporation, a
company based on stem cell research, for an undisclosed price.
Opposition has not abated with the current announcement. The
Vatican has condemned the decision as gravely immoral.
Representative Jay Dickey, an Arkansas Republican who sponsored
the 1996 ban, said that the new guidelines represented a boldfaced
violation of the law and that the [Clinton] administration
didn't have to bring this up right in the middle of the election.
Their concern is not so much with science as it is with promoting
the Clinton-Gore pro-abortion agenda.
A spokesperson for Republican presidential candidate George
W. Bush, Ray Sullivan, stated, Governor Bush opposes federal
funding for stem cell research when it involves destroying a living,
human embryo. Democratic vice presidential candidate Joseph
Lieberman has said that he and Gore support the new NIH guidelines.
The half-hearted nature of the new NIH guidelines highlights
the conflict between the profit motives of the biotech corporations,
which want to milk the discoveries for all they are worth, and
the political agenda of the right-wing religious forces, which
want to stifle scientific discovery altogether. Both influences
ultimately have a destructive effect on the full development of
this research.
See Also:
Scientists achieve cellular
transformation of bone marrow stem cells into nerve cells
[22 August 2000]
The human genome project:
science, society and superstition
[15 August 2000]
Human Genome Project: First
scientific milestone of the twenty-first century
[11 July 2000]
Top of page
The WSWS invites your comments.
Copyright 1998-2008
World Socialist Web Site
All rights reserved |